Amazon Adds 3.97% as Lilly Sits Flat in Its Buy Zone
Amazon closed up 3.97% at 266.43 and Eli Lilly slipped 0.13% to 1174.61 on Friday, as both landed on a seven-name screen built around analyst-favored earnings growth.

Amazon.com (AMZN) closed at 266.43 on Friday, Aug. 28, 2026, up 3.97% on the day, and Eli Lilly (LLY) closed at 1174.61, down 0.13%, as both appeared on an Investor's Business Daily screen of seven stocks favored by analysts for earnings growth.
Two of the largest names in American equities finished the week pointing in opposite directions, and both of them turned up on the same list of stocks screened for superior earnings growth. Amazon.com (AMZN) closed Friday, Aug. 28, 2026 at 266.43, a gain of 3.97% from the prior close of 256.26. Eli Lilly (LLY) closed at 1174.61, down 0.13% from 1176.10.
The screen behind the pairing, published by Investor's Business Daily, flags seven stocks as analyst favorites for earnings growth, with Lilly described as highly rated and sitting in a buy zone and Amazon described as holding a key level. Those two claims are testable against the closing tape, and that is where the interesting part is: one of them was confirmed emphatically on Friday, the other only quietly.
What Amazon's 3.97% day actually did to the chart
A near-4% move in a company of Amazon's size is not a rounding error. The stock traded as low as 257.78 and as high as 267.56 during the session before settling at 266.43 — meaning it finished within roughly 0.4% of its intraday peak, an illustrative calculation from the day's range rather than a reported figure. Closing at the top end of the daily range is the technical signature buyers want to see: it says the advance was not sold into as the session wore on.
Context sharpens it further. The Nasdaq 100, proxied by QQQ, fell 0.65% on the day to $716.43. The S&P 500 tracker SPY slipped 0.23% to $769.35, and the Dow tracker DIA was essentially unchanged at $535.06, off 0.03%. Amazon therefore beat the Nasdaq 100 by roughly 4.6 percentage points on the session — again an illustrative arithmetic comparison of the two supplied moves. Outperformance of that scale on a down day for large-cap technology is idiosyncratic. Something specific to Amazon, not a rising tide, moved the stock.
For chart-driven investors, "holding a key level" is a low bar cleared with room to spare when the stock advances almost 4% and shuts near its high. The more useful question for next week is whether the gain sticks. Single-session surges that immediately give back ground tend to be read as distribution — institutions selling into strength — while a quiet, low-volume consolidation above the new level is read as accumulation.
Lilly's buy zone survives on a technicality
Eli Lilly's Friday was the opposite kind of day: a 0.13% decline, a range of 1162.93 to 1180.00, and a close of 1174.61. In IBD's framework, a "buy zone" is the band immediately above the breakout point of a chart base — the range in which a stock is considered actionable rather than extended. A fractional dip does not remove a stock from that band. What it does is keep the stock waiting.
That matters because a buy zone has an expiry of sorts. Stocks that break out and then stall for weeks, drifting sideways within the zone without following through, frequently end up back inside their base. The bullish reading of Friday is that Lilly held its ground while the broad market softened and while capital visibly rotated toward Amazon. The bearish reading is that a stock with the earnings profile a screen like this demands should not need to grind.
Lilly also finished about 0.5% below its intraday high of 1180.00, on the same illustrative arithmetic basis — a mildly softer close pattern than Amazon's, though within the noise of a flat session.
Why earnings-growth screens are converging on the same handful of names
The premise of a screen built on analyst-favored earnings growth is that estimate revisions, not valuation, drive returns in a narrow market. Seven names is a very short list for a market of thousands of listed companies, and the fact that both a mega-cap platform business and a mega-cap pharmaceutical make the cut tells you something about where earnings momentum is currently concentrated: in businesses with pricing power, scale advantages and demand that analysts keep having to mark upward.
The premise of a screen built on analyst-favored earnings growth is that estimate revisions, not valuation, drive returns in a narrow market.
The risk in that concentration is symmetric. When the same names dominate every growth screen, every momentum fund and every index weighting, the marginal buyer becomes harder to find and the exit becomes crowded. Friday's tape showed how quickly the flow can swing — a down day for the Nasdaq 100 that was, for one of its largest constituents, a strongly positive one.
What to watch when trading resumes
Three specific things will determine whether the setups described in the screen remain intact:
- Amazon's follow-through. Does the stock hold above the area it reclaimed on Friday, or does it retrace back through 257.78, the session low? Holding the gain matters more than extending it.
- Lilly's direction out of its zone. A move above 1180.00, Friday's high, would confirm the buy zone thesis. Repeated closes drifting lower would suggest the breakout is failing.
- Whether the indexes cooperate. SPY, QQQ and DIA all closed lower or flat. Growth-stock breakouts historically have a poorer success rate when the broad market is in a downtrend, no matter how good the underlying earnings.
None of the closing figures above should be read as current prices. The market was shut when they were struck, at 20:00 GMT on Friday, Aug. 28, 2026, and the levels described are last-traded prices rather than live quotes. Investors acting on a buy zone need to reprice the zone against the next open, not against Friday's numbers.
The broader takeaway is less about either individual chart than about the divergence between them. On the same day, from the same list, one name delivered the kind of move that validates a screen and the other delivered almost nothing at all. Earnings growth explains why a stock qualifies for a list. It does not explain when the market will pay for it.
Key facts
- AMZN close (Aug. 28, 2026, 20:00 GMT): 266.43, +3.97%
- LLY close (Aug. 28, 2026, 20:00 GMT): 1174.61, -0.13%
- Nasdaq 100 (QQQ) close: $716.43, -0.65%
- Stocks on the earnings-growth screen: Seven, including Amazon and Eli Lilly
- Market status: Closed; figures are last-traded prices
Frequently asked questions
What were Amazon's and Eli Lilly's most recent closing prices?
As of the last trade at 20:00 GMT on Friday, Aug. 28, 2026, Amazon.com closed at 266.43, up 3.97% from a prior close of 256.26. Eli Lilly closed at 1174.61, down 0.13% from 1176.10. The market was closed when those prices were struck, so they are last-traded levels rather than live quotes.
What does it mean for a stock to be in a 'buy zone'?
A buy zone is the band of prices immediately above the point where a stock breaks out of a chart base. Within that band the breakout is considered actionable; above it the stock is treated as extended and a poorer risk-reward entry. Eli Lilly was described as highly rated and inside that band.
Did Amazon hold its key technical level?
On Friday's close it did, and comfortably. Amazon gained 3.97% and finished at 266.43, near the top of a session range of 257.78 to 267.56. Closing at the high end of the range suggests buyers were not sold into during the day. The test now is whether the gain holds when trading resumes.
How did Amazon's move compare with the broader market?
It ran against it. The Nasdaq 100 tracker QQQ fell 0.65% to $716.43, the S&P 500 tracker SPY slipped 0.23% to $769.35, and the Dow tracker DIA was flat at $535.06, down 0.03%. Amazon's 3.97% gain on a soft day for large-cap technology points to a company-specific driver.
How many stocks are on the earnings-growth list and who compiled it?
Seven stocks are described as analyst favorites for earnings growth in a screen published by Investor's Business Daily on Aug. 29, 2026. Amazon and Eli Lilly are the two named in the summary, with Lilly flagged as highly rated and in a buy zone and Amazon as holding a key level.
Why do earnings-growth screens keep surfacing the same mega-caps?
Screens built on analyst estimate revisions favor companies whose forecasts keep being marked higher, which tends to mean large firms with pricing power and scale. The consequence is concentration: the same names appear in momentum funds and index weightings, which can amplify moves in both directions when flows shift.
Sources
- These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Amazon Holds Key Level — Investors Business Daily
Photo: Elif · Pexels Licence — source


